Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate adverse reaction study of gadoterate meglumine in children younger than 2 years
ChiCTR1900022694Phase 4Recruiting
- Sponsor
- Tianjin Children's Hospital
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gadoterate meglumine, sponsored by Tianjin Children's Hospital. Primary endpoint: Acute adverse reaction rate within 1 hour after gadoterate meglumine injection. Started Jun 2018; status: recruiting.
02
Drugs
gadoterate meglumine
Beyond the preview
Go deeper on ChiCTR1900022694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022694.